These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 24325739)

  • 21. Therapeutics targeting CD90-integrin-AMPK-CD133 signal axis in liver cancer.
    Chen WC; Chang YS; Hsu HP; Yen MC; Huang HL; Cho CY; Wang CY; Weng TY; Lai PT; Chen CS; Lin YJ; Lai MD
    Oncotarget; 2015 Dec; 6(40):42923-37. PubMed ID: 26556861
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Novel Function for KLF4 in Modulating the De-differentiation of EpCAM
    Karagonlar ZF; Akbari S; Karabicici M; Sahin E; Avci ST; Ersoy N; Ates KE; Balli T; Karacicek B; Kaplan KN; Celiker C; Atabey N; Erdal E
    Cells; 2020 May; 9(5):. PubMed ID: 32408542
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of CD133+ parenchymal cells in the liver: histology and culture.
    Yoshikawa S; Zen Y; Fujii T; Sato Y; Ohta T; Aoyagi Y; Nakanuma Y
    World J Gastroenterol; 2009 Oct; 15(39):4896-906. PubMed ID: 19842219
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhanced tumorigenesis and lymphatic metastasis of CD133+ hepatocarcinoma ascites syngeneic cell lines mediated by JNK signaling pathway in vitro and in vivo.
    Jin Y; Mao J; Wang H; Hou Z; Ma W; Zhang J; Wang B; Huang Y; Zang S; Tang J; Li L
    Biomed Pharmacother; 2013 May; 67(4):337-45. PubMed ID: 23582787
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD133 silencing inhibits stemness properties and enhances chemoradiosensitivity in CD133-positive liver cancer stem cells.
    Lan X; Wu YZ; Wang Y; Wu FR; Zang CB; Tang C; Cao S; Li SL
    Int J Mol Med; 2013 Feb; 31(2):315-24. PubMed ID: 23233126
    [TBL] [Abstract][Full Text] [Related]  

  • 26. miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1.
    Ma S; Tang KH; Chan YP; Lee TK; Kwan PS; Castilho A; Ng I; Man K; Wong N; To KF; Zheng BJ; Lai PB; Lo CM; Chan KW; Guan XY
    Cell Stem Cell; 2010 Dec; 7(6):694-707. PubMed ID: 21112564
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biologic characteristics of the side population of human small cell lung cancer cell line H446.
    Wang B; Yang H; Huang YZ; Yan RH; Liu FJ; Zhang JN
    Chin J Cancer; 2010 Mar; 29(3):254-60. PubMed ID: 20193106
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CD133+ liver cancer stem cells resist interferon-gamma-induced autophagy.
    Li J; Chen JN; Zeng TT; He F; Chen SP; Ma S; Bi J; Zhu XF; Guan XY
    BMC Cancer; 2016 Jan; 16():15. PubMed ID: 26758620
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A robust culture method for maintaining tumorigenic cancer stem cells in the hepatocellular carcinoma cell line Li-7.
    Sato Y; Yamada T; Hiroyama T; Sudo K; Hasegawa N; Hyodo I; Nakamura Y
    Cancer Sci; 2019 May; 110(5):1644-1652. PubMed ID: 30784169
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling.
    Tang KH; Ma S; Lee TK; Chan YP; Kwan PS; Tong CM; Ng IO; Man K; To KF; Lai PB; Lo CM; Guan XY; Chan KW
    Hepatology; 2012 Mar; 55(3):807-20. PubMed ID: 21994122
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma.
    Kohga K; Tatsumi T; Takehara T; Tsunematsu H; Shimizu S; Yamamoto M; Sasakawa A; Miyagi T; Hayashi N
    J Hepatol; 2010 Jun; 52(6):872-9. PubMed ID: 20395004
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Arsenite inhibits the function of CD133
    Tang H; Jin Y; Jin S; Tan Z; Peng Z; Kuang Y
    Tumour Biol; 2016 Oct; 37(10):14103-14115. PubMed ID: 27517564
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Expression of CD90/EpCAM/CD24 in hepatocellular carcinoma cell lines at various stages of differentiation].
    Chen BD; Hui YF; Zhang HB; Fan LF; Si MH; Yang GS
    Zhonghua Gan Zang Bing Za Zhi; 2013 Sep; 21(9):688-91. PubMed ID: 24160345
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vivo investigation of CD133 as a putative marker of cancer stem cells in Hep-2 cell line.
    Wei XD; Zhou L; Cheng L; Tian J; Jiang JJ; Maccallum J
    Head Neck; 2009 Jan; 31(1):94-101. PubMed ID: 18853445
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Surface markers of hepatocellular cancer stem cells and their clinical potential.
    Feng D; Wang N; Hu J; Li W
    Neoplasma; 2014; 61(5):505-13. PubMed ID: 24712843
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High CD133 expression levels in gastrointestinal stromal tumors.
    Bozzi F; Conca E; Manenti G; Negri T; Brich S; Gronchi A; Pierotti MA; Tamborini E; Pilotti S
    Cytometry B Clin Cytom; 2011; 80(4):238-47. PubMed ID: 21462307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Active glycolytic metabolism in CD133(+) hepatocellular cancer stem cells: regulation by MIR-122.
    Song K; Kwon H; Han C; Zhang J; Dash S; Lim K; Wu T
    Oncotarget; 2015 Dec; 6(38):40822-35. PubMed ID: 26506419
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ANXA3/JNK Signaling Promotes Self-Renewal and Tumor Growth, and Its Blockade Provides a Therapeutic Target for Hepatocellular Carcinoma.
    Tong M; Fung TM; Luk ST; Ng KY; Lee TK; Lin CH; Yam JW; Chan KW; Ng F; Zheng BJ; Yuan YF; Xie D; Lo CM; Man K; Guan XY; Ma S
    Stem Cell Reports; 2015 Jul; 5(1):45-59. PubMed ID: 26095609
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Elevated expression of the stem cell marker CD133 associated with Line-1 demethylation in hepatocellular carcinoma.
    Zhang C; Xu Y; Zhao J; Fan L; Jiang G; Li R; Ling Y; Wu M; Wei L
    Ann Surg Oncol; 2011 Aug; 18(8):2373-80. PubMed ID: 21331808
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased CD13 expression reduces reactive oxygen species, promoting survival of liver cancer stem cells via an epithelial-mesenchymal transition-like phenomenon.
    Kim HM; Haraguchi N; Ishii H; Ohkuma M; Okano M; Mimori K; Eguchi H; Yamamoto H; Nagano H; Sekimoto M; Doki Y; Mori M
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S539-48. PubMed ID: 21879266
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.